BOXED WARNING Can cause marked elevation of supine BP; reserve for symptomatic orthostatic hypotension considerably impairing daily life; clinical benefit (activities of daily living) not verified (approved on surrogate marker)
FDA dosing
Population
Start
Target
Max
Symptomatic orthostatic hypotension
Adult
10 mg TID (daytime, ~4 h apart)
10 mg TID
single doses ≤20 mg studied; >30 mg/day not established
Orthostatic hypotension
Renal impairment
2.5 mg TID
Renal Initiate at 2.5 mg; dose cautiously (desglymidodrine excreted renally)
Hepatic Undefined
Doses may be spaced at 3-h intervals if needed to control symptoms, but not more frequently
Instructions
Dose during daytime upright hours: on arising, midday, and late afternoon (not later than 6 PM)
Do not give after the evening meal or <4 h before bedtime (supine hypertension risk)
Monitor supine and standing BP; stop if supine BP rises excessively; continue only if symptomatic improvement
Contraindications
Severe organic heart disease
Acute renal disease
Urinary retention
Pheochromocytoma
Thyrotoxicosis
Persistent and excessive supine hypertension
Cautions
Supine hypertension (most serious) — monitor supine/standing BP
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.